The Kidney as a Treatment Target for Type 2 Diabetes

Author:

Dokken Betsy

Abstract

Abstract Type 2 diabetes is a complex and progressive disease that affects 8.3% of the U.S. population. Despite the availability of numerous treatment options for type 2 diabetes, the proportion of patients achieving glycemic goals is unacceptably low; therefore, new pharmacotherapies are needed to promote glycemic control in these patients. The kidney normally reabsorbs 99% of filtered glucose and returns it to the circulation. Glucose reabsorption by the kidney is mediated by sodium-glucose co-transporters (SGLTs), mainly SGLT2. SGLT2 inhibition presents an additional option to promote glycemic control in patients with type 2 diabetes. A number of SGLT2 inhibitors have been synthesized and are in various stages of clinical development for the treatment of type 2 diabetes. Results from clinical trials show that these compounds decrease plasma glucose and body weight in treatment-naive patients and in patients receiving metformin or insulin and insulin sensitizers. Overall, SGLT2 inhibitors appear to be generally well tolerated, but in some studies, signs, symptoms, and other reports of genital and urinary tract infections have been more frequent in drug-treated groups than in placebo groups. Additional clinical trials will determine whether this class of compounds with a unique, insulin-independent mechanism of action becomes a treatment option for reducing hyperglycemia in type 2 diabetes.

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference82 articles.

1. World Health Organization : Diabetes: fact sheet no. 312 [article online]. Available from http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 2 June 2011

2. Centers for Disease Control : National diabetes fact sheet, 2007 [article online]. Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed 12 January 2011

3. Standards of medical care in diabetes—2012;American Diabetes Association;Diabetes Care,2012

4. Microvascular complications of impaired glucose tolerance;Singleton;Diabetes,2003

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3